In cancer, dual blockade of DDR2 and Intαv subfamily (ITGAV) via siRNA-loaded nanocarriers has been pursued as a strategy to overcome matrix barriers to enhance immune infiltration in preclinical models of breast cancer. This evidence concerns the gene DDR2 and breast cancer.